#	Pagina
attuale pagina	/open-h2020/projects/226152/index.html

Opendata, web and dolomites

TheraLymph SIGNED

Gene Therapy to restore lymphatic flow lymphedema

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

TheraLymph project word cloud

Explore the words cloud of the TheraLymph project. It provides you a very rough idea of what is the project "TheraLymph" about.

medical integrative deeper endothelium efficient diseases synergistic trial pathology vivo scientists accumulation clinical lentiflash transient generally performed toulouse hospital lymphedematous gene rangueil drainage pi modified hosted validate cartography vascular lymphangiogenic unmet women disease molecules restores worldwide arm preclinical possess people translational life bench painful breast substantially lipids innovative risk theralymph network quality millions brings perform ten handicapping models disabling combination human vectors effect fifteen physicians monotherapy western decipher fluid leg consequence 120 percent impacts molecule therapy lymphatic collectors lentiviral intrinsic treatments decades dysfunction laboratory vegfc superficial multiple peptides medicine lymphedema fat cardiovascular located microenvironmental countries untreatable disappointing cancer

Project "TheraLymph" data sheet

The following table provides information about the project.

Coordinator	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	8˙064˙946 €
EC max contribution	8˙064˙946 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2019-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-01-01 to 2024-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	1˙475˙531.00
2	FLASH THERAPEUTICS FLASH THERAPEUTICS Organization address address: CANAL BIOTECH II - 3 RUE DES SATELLITES city: TOULOUSE postcode: 31400 website: www.vectalys.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (TOULOUSE)	participant	1˙132˙908.00
3	HELSINGIN YLIOPISTO HELSINGIN YLIOPISTO Organization address address: YLIOPISTONKATU 3 city: HELSINGIN YLIOPISTO postcode: 14 website: www.helsinki.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (HELSINGIN YLIOPISTO)	participant	1˙046˙198.00
4	CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE Organization address address: RUE VIGUERIE 2 HOTEL DIEU SAINT JACQUES city: TOULOUSE CEDEX 3 postcode: 31052 website: www.chu-toulouse.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (TOULOUSE CEDEX 3)	participant	947˙000.00
5	UNIVERSITE DE LAUSANNE UNIVERSITE DE LAUSANNE Organization address address: Quartier Unil-Centre Bâtiment Unicentre city: LAUSANNE postcode: 1015 website: www.unil.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (LAUSANNE)	participant	868˙185.00
6	UNIVERSITE DE LIEGE UNIVERSITE DE LIEGE Organization address address: PLACE DU 20 AOUT 7 city: LIEGE postcode: 4000 website: www.ulg.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (LIEGE)	participant	706˙250.00
7	DE DUVE INSTITUTE DE DUVE INSTITUTE Organization address address: AVENUE HIPPOCRATE 75 city: BRUXELLES postcode: 1200 website: www.deduveinstitute.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	608˙335.00
8	UPPSALA UNIVERSITET UPPSALA UNIVERSITET Organization address address: VON KRAEMERS ALLE 4 city: UPPSALA postcode: 751 05 website: www.uu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	participant	455˙000.00
9	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS Organization address address: RUE MICHEL ANGE 3 city: PARIS postcode: 75794 website: www.cnrs.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	317˙287.00
10	UNIVERZITA KARLOVA UNIVERZITA KARLOVA Organization address address: OVOCNY TRH 560/5 city: PRAHA 1 postcode: 116 36 website: www.cuni.cz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (PRAHA 1)	participant	293˙750.00
11	INSERM - TRANSFERT SA INSERM - TRANSFERT SA Organization address address: RUE WATT 7 city: PARIS postcode: 75013 website: www.inserm-transfert.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	214˙500.00

Map

Project objective

Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg. It is an untreatable disease that affects 4 millions people in Europe and more than 120 millions people worldwide. It is handicapping, painful and impacts substantially the quality of life. In western countries, lymphedema is generally a consequence of cancer treatments i.e. ten to fifteen percent of women will develop lymphedema after breast cancer. The main objective of Theralymph will be to establish a non-integrative gene therapy for this unmet medical need. The theralymph translational research program brings together bench scientists from 5 European countries and physicians from the hosted Rangueil hospital in which the PI institute is located to perform a Phase I/II trial focusing on women who developed lymphedema after breast cancer. Based on decades of disappointing results of monotherapy-gene delivery in cardiovascular diseases, our approach will be based on multiple gene therapy targeting both superficial lymphatic endothelium and deeper lymphatic collectors. We will identify molecules that possess a synergistic effect with the established lymphangiogenic factor VEGFC. Theralymph project will determine risk factors for lymphedema and cartography the lymphatic network in the pathology. It will decipher whether lymphatic intrinsic molecules or microenvironmental peptides or lipids are modified in the lymphedematous arm to promote the lymphatic dysfunction. Theralymph will validate the best molecule combination that restores the lymphatic drainage in in preclinical lymphedema models before human study. The Phase I/II gene therapy clinical trial will be performed in the vascular medicine department of Toulouse’s hospital, where the PI laboratory is located. This trial will use an innovative technology based on recently developed non-integrative lentiflash lentiviral vectors that allow a transient and highly efficient in vivo gene delivery.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERALYMPH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERALYMPH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More